{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T14:34:25Z","timestamp":1787063665895,"version":"build-2736575974"},"reference-count":50,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Autoimmunity"],"published-print":{"date-parts":[[2021,9]]},"DOI":"10.1016\/j.jaut.2021.102704","type":"journal-article","created":{"date-parts":[[2021,7,20]],"date-time":"2021-07-20T14:06:43Z","timestamp":1626790003000},"page":"102704","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"special_numbering":"C","title":["Interferon (IFN)-stimulated gene 15: A novel biomarker for lymphoma development in Sj\u00f6gren's syndrome"],"prefix":"10.1016","volume":"123","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2362-5591","authenticated-orcid":false,"given":"Ilir I.","family":"Cinoku","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kleio-Maria","family":"Verrou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evangelia","family":"Piperi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Voulgarelis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haralampos M.","family":"Moutsopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clio P.","family":"Mavragani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaut.2021.102704_bib1","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1503\/cmaj.122037","article-title":"Sj\u00f6gren syndrome","volume":"186","author":"Mavragani","year":"2014","journal-title":"CMAJ (Can. Med. Assoc. J.)"},{"key":"10.1016\/j.jaut.2021.102704_bib2","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/j.jaut.2012.05.011","article-title":"Endocrine alterations in primary Sjogren's syndrome: an overview","volume":"39","author":"Mavragani","year":"2012","journal-title":"J. Autoimmun."},{"key":"10.1016\/j.jaut.2021.102704_bib3","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.1001\/archinte.165.20.2337","article-title":"The risk of lymphoma development in autoimmune diseases: a meta-analysis","volume":"165","author":"Zintzaras","year":"2005","journal-title":"Arch. Intern. Med."},{"key":"10.1016\/j.jaut.2021.102704_bib4","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/S0049-0172(00)80016-5","article-title":"Clinical evolution, and morbidity and mortality of primary Sjogren's syndrome","volume":"29","author":"Skopouli","year":"2000","journal-title":"Semin. Arthritis Rheum."},{"key":"10.1016\/j.jaut.2021.102704_bib5","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1002\/art.10221","article-title":"Long-term risk of mortality and lymphoproliferative disease and predictive classification of primary Sj\u00f6gren\u2019s syndrome","volume":"46","author":"Ioannidis","year":"2002","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.jaut.2021.102704_bib6","first-page":"1","article-title":"Predicting the risk for lymphoma development in Sjogren syndrome","volume":"95","author":"Fragkioudaki","year":"2016","journal-title":"Med. (United States)"},{"key":"10.1016\/j.jaut.2021.102704_bib7","doi-asserted-by":"crossref","first-page":"102317","DOI":"10.1016\/j.jaut.2019.102317","article-title":"Genetic contributors and soluble mediators in prediction of autoimmune comorbidity","volume":"104","author":"Nezos","year":"2019","journal-title":"J. Autoimmun."},{"key":"10.1016\/j.jaut.2021.102704_bib8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s40674-020-00138-x","article-title":"Lymphoma in Sj\u00f6gren\u2019s syndrome: predictors and therapeutic options","volume":"6","author":"Skarlis","year":"2020","journal-title":"Curr. Treat. Options Rheumatol."},{"key":"10.1016\/j.jaut.2021.102704_bib9","doi-asserted-by":"crossref","first-page":"102648","DOI":"10.1016\/j.jaut.2021.102648","article-title":"A biomarker for lymphoma development in Sjogren's syndrome: salivary gland focus score","volume":"121","author":"Chatzis","year":"2021","journal-title":"J. Autoimmun."},{"key":"10.1016\/j.jaut.2021.102704_bib10","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jaut.2014.01.001","article-title":"Sj\u00f6gren\u2019s syndrome: a forty-year scientific journey","volume":"51","author":"Moutsopoulos","year":"2014","journal-title":"J. Autoimmun."},{"key":"10.1016\/j.jaut.2021.102704_bib11","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1056\/NEJM197907053010102","article-title":"Immune interferon in the circulation of patients with autoimmune disease","volume":"301","author":"Hooks","year":"1979","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jaut.2021.102704_bib12","doi-asserted-by":"crossref","first-page":"2686","DOI":"10.1002\/art.39795","article-title":"Expression of long interspersed nuclear element 1 retroelements and induction of type I interferon in patients with systemic autoimmune disease","volume":"68","author":"Mavragani","year":"2016","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.jaut.2021.102704_bib13","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.jaut.2015.07.002","article-title":"Type I and II interferon signatures in Sjogren's syndrome pathogenesis: contributions in distinct clinical phenotypes and Sjogren's related lymphomagenesis","volume":"63","author":"Nezos","year":"2015","journal-title":"J. Autoimmun."},{"key":"10.1016\/j.jaut.2021.102704_bib14","first-page":"S185","article-title":"Type I interferon signature in Sj\u00f6gren\u2019s syndrome: pathophysiological and clinical implications","volume":"37","author":"Marketos","year":"2019","journal-title":"Clin. Exp. Rheumatol."},{"key":"10.1016\/j.jaut.2021.102704_bib15","first-page":"921","article-title":"Systemic interferon type I and type II signatures in primary Sj\u00f6gren\u2019s syndrome reveal differences in biological disease activity","volume":"57","author":"Bodewes","year":"2018","journal-title":"Rheumatol. (United Kingdom)."},{"key":"10.1016\/j.jaut.2021.102704_bib16","doi-asserted-by":"crossref","first-page":"2437","DOI":"10.1002\/art.39204","article-title":"Molecular subsetting of interferon pathways in Sj\u00f6gren\u2019s syndrome","volume":"67","author":"Hall","year":"2015","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.jaut.2021.102704_bib17","doi-asserted-by":"crossref","first-page":"154781","DOI":"10.1016\/j.cyto.2019.154781","article-title":"TREX1 variants in Sjogren's syndrome related lymphomagenesis","volume":"132","author":"Nezos","year":"2020","journal-title":"Cytokine"},{"key":"10.1016\/j.jaut.2021.102704_bib18","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.jaut.2017.10.004","article-title":"Defective regulation of L1 endogenous retroelements in primary Sjogren's syndrome and systemic lupus erythematosus: role of methylating enzymes","volume":"88","author":"Mavragani","year":"2018","journal-title":"J. Autoimmun."},{"key":"10.1016\/j.jaut.2021.102704_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.clim.2020.108649","article-title":"Expression of APOBEC family members as regulators of endogenous retroelements and malignant transformation in systemic autoimmunity","volume":"223","author":"Mavragani","year":"2021","journal-title":"Clin. Immunol."},{"key":"10.1016\/j.jaut.2021.102704_bib20","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1136\/annrheumdis-2016-210571","article-title":"American College of Rheumatology\/European League against Rheumatism classification criteria for primary Sj\u00f6gren\u2019s syndrome: a consensus and data-driven methodology involving three international patient cohorts","volume":"76","author":"Shiboski","year":"2016","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jaut.2021.102704_bib21","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1182\/blood.V84.5.1361.1361","article-title":"A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group","volume":"84","author":"Harris","year":"1994","journal-title":"Blood"},{"key":"10.1016\/j.jaut.2021.102704_bib22","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1002\/1529-0131(199908)42:8<1765::AID-ANR28>3.0.CO;2-V","article-title":"Malignant lymphoma in primary Sjogren's syndrome: a multicenter, retrospective, clinical study by the European concerted action on Sjogren's syndrome","volume":"42","author":"Voulgarelis","year":"1999","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.jaut.2021.102704_bib23","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1002\/art.40930","article-title":"European league against rheumatism\/American college of Rheumatology classification criteria for systemic lupus erythematosus","volume":"71","author":"Aringer","year":"2019","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.jaut.2021.102704_bib24","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1136\/ard.2010.138461","article-title":"Rheumatoid arthritis classification criteria\u00a0: an American College of Rheumatology\/European League against Rheumatism collaborative initiative","volume":"69","author":"Aletaha","year":"2010","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jaut.2021.102704_bib25","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.autrev.2006.03.004","article-title":"Undifferentiated connective tissue diseases (UCTD)","volume":"6","author":"Mosca M","year":"2006","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.jaut.2021.102704_bib26","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.3899\/jrheum.100594","article-title":"Fibromyalgia criteria and severity scales for clinical and epidemiological Studies\u202f: a modification of the ACR preliminary diagnostic criteria for fibromyalgia criteria and severity scales for clinical and epidemiological studies","volume":"38","author":"Wolfe","year":"2011","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.jaut.2021.102704_bib27","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1111\/1346-8138.14161","article-title":"Diagnostic criteria , severity classification and guidelines of localized scleroderma","volume":"45","author":"Asano","year":"2018","journal-title":"J. Dermatol."},{"key":"10.1016\/j.jaut.2021.102704_bib28","doi-asserted-by":"crossref","DOI":"10.1002\/art.21890","article-title":"Functional assay of type I interferon in systemic lupus erythematosus plasma and association with anti-RNA binding protein autoantibodies","volume":"54","author":"Hua","year":"2006","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.jaut.2021.102704_bib29","doi-asserted-by":"crossref","first-page":"17609","DOI":"10.1073\/pnas.1209724109","article-title":"Precise probes of type II interferon activity define the origin of interferon signatures in target tissues in rheumatic diseases","volume":"109","author":"Hall","year":"2012","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.jaut.2021.102704_bib30","doi-asserted-by":"crossref","first-page":"3958","DOI":"10.1002\/art.20798","article-title":"Coordinate overexpression of interferon-\u03b1-induced genes in systemic lupus erythematosus","volume":"50","author":"Kirou","year":"2004","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.jaut.2021.102704_bib31","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1038\/s41579-018-0020-5","article-title":"ISG15 in antiviral immunity and beyond","volume":"16","author":"Perng","year":"2018","journal-title":"Nat. Rev. Microbiol."},{"key":"10.1016\/j.jaut.2021.102704_bib32","doi-asserted-by":"crossref","first-page":"4100","DOI":"10.4049\/jimmunol.157.9.4100","article-title":"In vitro and in vivo secretion of human ISG15, an IFN-induced immunomodulatory cytokine","volume":"157","author":"D'Cunha","year":"1996","journal-title":"J. Immunol."},{"key":"10.1016\/j.jaut.2021.102704_bib33","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1007\/s00393-017-0274-8","article-title":"Interferon-stimulated gene 15 expression in systemic lupus erythematosus: diagnostic value and association with lymphocytopenia","volume":"77","author":"Yuan","year":"2018","journal-title":"Z. Rheumatol."},{"key":"10.1016\/j.jaut.2021.102704_bib34","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1002\/ana.21805","article-title":"Interferon-stimulated gene 15 (ISG15) conjugates proteins in dermatomyositis muscle with perifascicular atrophy","volume":"67","author":"Salajegheh","year":"2010","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.jaut.2021.102704_bib35","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1056\/NEJMra1402225","article-title":"Inflammatory muscle diseases","volume":"372","author":"Dalakas","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jaut.2021.102704_bib36","doi-asserted-by":"crossref","first-page":"7309","DOI":"10.1158\/0008-5472.CAN-14-1354","article-title":"ISG15 is a critical microenvironmental factor for pancreatic cancer stem cells","volume":"74","author":"Sainz","year":"2014","journal-title":"Canc. Res."},{"key":"10.1016\/j.jaut.2021.102704_bib37","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.canlet.2018.09.007","article-title":"ISG15 in cancer: beyond ubiquitin-like protein","volume":"438","author":"Han","year":"2018","journal-title":"Canc. Lett."},{"key":"10.1016\/j.jaut.2021.102704_bib38","first-page":"3751","article-title":"Knockdown of interferon-stimulated gene 15 affects the sensitivity of hepatocellular carcinoma cells to norcantharidin","author":"Chen","year":"2019","journal-title":"Exp. Ther. Med."},{"key":"10.1016\/j.jaut.2021.102704_bib39","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1258\/ebm.2011.011236","article-title":"ISG15 disrupts cytoskeletal architecture and promotes motility in human breast cancer cells","volume":"237","author":"Desai","year":"2012","journal-title":"Exp. Biol. Med."},{"key":"10.1016\/j.jaut.2021.102704_bib40","doi-asserted-by":"crossref","first-page":"4107","DOI":"10.1038\/onc.2011.577","article-title":"SULF2 methylation is prognostic for lung cancer survival and increases sensitivity to topoisomerase-I inhibitors via induction of ISG15","volume":"31","author":"Tessema","year":"2012","journal-title":"Oncogene"},{"key":"10.1016\/j.jaut.2021.102704_bib41","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1038\/sj.bjc.6603099","article-title":"Stage-associated overexpression of the ubiquitin-like protein, ISG15, in bladder cancer","volume":"94","author":"Andersen","year":"2006","journal-title":"Br. J. Canc."},{"key":"10.1016\/j.jaut.2021.102704_bib42","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1126\/science.1224026","article-title":"Mycobacterial disease and impaired IFN-\u03b3 immunity in humans with inherited ISG15 deficiency","volume":"337","author":"Bogunovic","year":"2012","journal-title":"Science"},{"key":"10.1016\/j.jaut.2021.102704_bib43","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1073\/pnas.93.1.211","article-title":"Immunoregulatory properties of ISG15, an interferon-induced cytokine","volume":"93","author":"Cunha","year":"1996","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.jaut.2021.102704_bib44","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1038\/nature13801","article-title":"Human intracellular ISG15 prevents interferon-\u03b1\/\u03b2 over-amplification and auto-inflammation","volume":"517","author":"Zhang","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.jaut.2021.102704_bib45","doi-asserted-by":"crossref","first-page":"2770","DOI":"10.1073\/pnas.0510837103","article-title":"Activation of IFN pathways and plasmacytoid dendritic cell recruitment in target organs of primary Sj\u00f6gren\u2019s syndrome","volume":"103","author":"Gottenberg","year":"2006","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.jaut.2021.102704_bib46","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.1002\/eji.200738008","article-title":"Systemic increase in type I interferon activity in Sj\u00f6gren\u2019s syndrome: a putative role for plasmacytoid dendritic cells","volume":"38","author":"Wildenberg","year":"2008","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.jaut.2021.102704_bib47","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/S0002-9440(10)61689-6","article-title":"Plasmacytoid dendritic cells (natural interferon-\u03b1\/\u03b2-producing cells) accumulate in cutaneous lupus erythematosus lesions","volume":"159","author":"Farkas","year":"2001","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.jaut.2021.102704_bib48","doi-asserted-by":"crossref","first-page":"4062","DOI":"10.4049\/jimmunol.165.7.4062","article-title":"Experimentally induced recruitment of plasmacytoid (CD123 high ) dendritic cells in human nasal allergy","volume":"165","author":"Jahnsen","year":"2000","journal-title":"J. Immunol."},{"key":"10.1016\/j.jaut.2021.102704_bib49","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1038\/11360","article-title":"Plasmacytoid monocytes migrate to inflamed lymph nodes and produce large amounts of type I interferon","volume":"5","author":"Cella","year":"1999","journal-title":"Nat. Med."},{"key":"10.1016\/j.jaut.2021.102704_bib50","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/S1359-6101(01)00038-7","article-title":"The roles of IFN\u03b3 in protection against tumor development and cancer immunoediting","volume":"13","author":"Ikeda","year":"2002","journal-title":"Cytokine Growth Factor Rev."}],"container-title":["Journal of Autoimmunity"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0896841121001128?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0896841121001128?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T08:29:51Z","timestamp":1760257791000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0896841121001128"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9]]},"references-count":50,"alternative-id":["S0896841121001128"],"URL":"https:\/\/doi.org\/10.1016\/j.jaut.2021.102704","relation":{},"ISSN":["0896-8411"],"issn-type":[{"value":"0896-8411","type":"print"}],"subject":[],"published":{"date-parts":[[2021,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Interferon (IFN)-stimulated gene 15: A novel biomarker for lymphoma development in Sj\u00f6gren's syndrome","name":"articletitle","label":"Article Title"},{"value":"Journal of Autoimmunity","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaut.2021.102704","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"102704"}}